Yupeng Feng,Meng Yuan,Mengyun Hu,Lorenza Bellusci,JungHyun Kim,Sumana Sundaramurthy,Xueyong Zhu,Alberto Moreno,Harry Kleanthous,David Veesler,Surender Khurana,Bali Pulendran,John M. Powers,Jennifer E. Munt,Prabhu S. Arunachalam,Sarah R. Leist,Kaitlin R. Sprouse,Lily E. Adams,Lisa M. Shirreff,Michael L. Mallory,Trevor D. Scobey,Derek T. O'Hagan,Francois J. Villinger,Neil P. King,Mehul S. Suthar,Ralph S. Baric,Ian A. Wilson

Abstract:The rapid emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants that evade immunity elicited by vaccination has placed an imperative on the development of countermeasures that provide broad protection against SARS-CoV-2 and related sarbecoviruses. Here, we identified extremely potent monoclonal antibodies (mAbs) that neutralized multiple sarbecoviruses from macaques vaccinated with AS03-adjuvanted monovalent subunit vaccines. Longitudinal analysis revealed progressive accumulation of somatic mutation in the immunoglobulin genes of antigen-specific memory B cells (MBCs) for at least 1 year after primary vaccination. Antibodies generated from these antigen-specific MBCs at 5 to 12 months after vaccination displayed greater potency and breadth relative to those identified at 1.4 months. Fifteen of the 338 (about 4.4%) antibodies isolated at 1.4 to 6 months after the primary vaccination showed potency against SARS-CoV-2 BA.1, despite the absence of serum BA.1 neutralization. 25F9 and 20A7 neutralized authentic clade 1 sarbecoviruses (SARS-CoV, WIV-1, SHC014, SARS-CoV-2 D614G, BA.1, and Pangolin-GD) and vesicular stomatitis virus–pseudotyped clade 3 sarbecoviruses (BtKY72 and PRD-0038). 20A7 and 27A12 showed potent neutralization against all SARS-CoV-2 variants and multiple Omicron sublineages, including BA.1, BA.2, BA.3, BA.4/5, BQ.1, BQ.1.1, and XBB. Crystallography studies revealed the molecular basis of broad and potent neutralization through targeting conserved sites within the RBD. Prophylactic protection of 25F9, 20A7, and 27A12 was confirmed in mice, and administration of 25F9 particularly provided complete protection against SARS-CoV-2, BA.1, SARS-CoV, and SHC014 challenge. These data underscore the extremely potent and broad activity of these mAbs against sarbecoviruses.

Mosaic RBD nanoparticles protect against multiple sarbecovirus challenges in animal models

Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models

Mosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animals

Designed mosaic nanoparticles enhance cross-reactive immune responses in mice

Mosaic RBD Nanoparticles Elicit Protective Immunity Against Multiple Human Coronaviruses in Animal Models

Mosaic RBD nanoparticle elicits immunodominant antibody responses across sarbecoviruses

Broadly neutralizing antibodies against sarbecoviruses generated by immunization of macaques with an AS03-adjuvanted COVID-19 vaccine

Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice

A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice

Multi-antigen intranasal vaccine protects against challenge with sarbecoviruses and prevents transmission in hamsters

Broad sarbecovirus neutralization by combined memory B cell antibodies to ancestral SARS-CoV-2

Broad protection against clade 1 sarbecoviruses after a single immunization with cocktail spike-protein-nanoparticle vaccine

A computationally designed antigen eliciting broad humoral responses against SARS-CoV-2 and related sarbecoviruses

A multi-specific, multi-affinity antibody platform neutralizes sarbecoviruses and confers protection against SARS-CoV-2 in vivo

Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability

Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses

A Single Chimeric Spike Antigen Induces Pan-Sarbecovirus Immunity

Quadrivalent mosaic HexaPro-bearing nanoparticle vaccine protects against infection of SARS-CoV-2 variants

Broad sarbecovirus neutralization by a human monoclonal antibody

Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine